EDIT-103

**EDIT-103** is an experimental **CRISPR-based gene therapy** developed by **Editas Medicine** for **rhodopsin-associated autosomal dominant retinitis pigmentosa**. It was designed as a dual-AAV, subretinally delivered knockout-and-replace approach in which CRISPR/Cas9 editing is used to disrupt mutant **RHO** alleles while providing a replacement rhodopsin coding sequence intended to preserve photoreceptor function. The program was positioned to address a broad range of disease-causing **RHO** mutations rather than a single variant, but it remained **preclinical** and was later **discontinued** during Editas Medicine's 2023 portfolio reprioritization.